Myriad Genetics, Inc. (MYGN) News

Myriad Genetics, Inc. (MYGN): $19.49

-0.12 (-0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MYGN News Items

MYGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MYGN News Highlights

  • For MYGN, its 30 day story count is now at 8.
  • Over the past 19 days, the trend for MYGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • NOV, ST and TALK are the most mentioned tickers in articles about MYGN.

Latest MYGN News From Around the Web

Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction. “Genetic testing is an essential tool across the continuu

Yahoo | November 29, 2022

Investing in Myriad Genetics Inc. (MYGN) might be an excellent idea, but the stock is currently overvalued/undervalued

Myriad Genetics Inc. (NASDAQ:MYGN) marked $19.96 per share on Wednesday, down from a previous closing price of $20.88. While Myriad Genetics Inc. has underperformed by -4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -33.20%, with highs and lows ranging from $30.29 to […]

US Post News | November 17, 2022

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can provide better overall care, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN). Yet, results of the Spring 202

Yahoo | November 17, 2022

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41 st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.

GlobeNewswire | November 14, 2022

Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment

Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.

Yahoo | November 14, 2022

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.

GlobeNewswire | November 10, 2022

Results from Myriad Genetics Inc. (MYGN) show risk

In Wednesday’s session, Myriad Genetics Inc. (NASDAQ:MYGN) marked $16.30 per share, down from $17.50 in the previous session. While Myriad Genetics Inc. has underperformed by -6.86%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -47.08%, with highs and lows ranging from $32.00 to […]

US Post News | November 3, 2022

Myriad Genetics Q3 2022 Earnings: Hold (MYGN)

In Q3 2022, Myriad Genetics demonstrated weak performance in most of its core business segments. See why I rate MYGN stock a hold.

Seeking Alpha | November 3, 2022

Why Shares of Myriad Genetics Dropped 24% This Week

The genetic-testing company announced an acquisition and lowered its guidance.

The Motley Fool | November 3, 2022

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study1 that highlights the development and validation of a breast cancer polygenic risk score (PRS) for women of all ancestries. “PRS is one of the most powerful risk prediction tools in the field of breast cancer, and until recently a validated model had not been available to assess women of all ancest

Yahoo | November 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5603 seconds.